Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

Pessôa, Mário; Gazzard, Brian; Huang, Andrew; Brandão‐Mello, Carlos Eduardo; Cassetti, Isabel; Mendes-Corrêa, Maria Cássia; Soriano, Vincent; Phiri, Phillip; Hall, Andrea C.; Brett‐Smith, Helena

doi:10.1097/qad.0b013e32830b3ab5

Cited by 48 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the large number of studies worldwide addressing the different therapeutic strategies and their clinical and virological consequences, only a few studies reporting the situation of antiviral treatment in Brazil are available; however, most of these studies have described the occurrence of LAM-resistance mutations (Da Silva et al 2001, Bottecchia et al 2008a, b, Haddad et al 2010, particularly in HIV/HBV co-infected patients (Santos et al 2004, Sucupira et al 2006, Pessoa et al 2008. Recent studies, concerning the genotypes endemic in Asia and Europe, have shown that the genotypic profile may play a role in a number of factors, including the emergence of mutations, the severity of liver disease, clinical outcome and response to antiviral therapies (Orito In accordance to previous observations (Gauthier et al 1999, Mommeja-Marin et al 2003, Keeffe et al 2007, this study demonstrated a significant association between elevated ALT levels and positivity of HBV DNA.…”

Section: Discussionmentioning

confidence: 99%

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes

Ca²,

Gomes

2012

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes

Ca²,

Gomes

2012

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

“…Nevertheless, all HIV co-infected patients with serum HBsAb negativity and HBsAg positivity should be vaccinated for HBV [51,52] . Although low CD4 cell counts are associated with an impaired response to vaccination, HBV vaccination should not be deferred for patients with advanced HIV, as some individuals do develop protective antibody titers despite low CD4 cell counts.…”

Section: Challengesmentioning

confidence: 99%

HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches

Parvez¹

2015

WJH

View full text Add to dashboard Cite

The consequences of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection on progression of severe liver diseases is a serious public health issue, worldwide. In the co-infection cases, about 90% of HIV-infected population is seropositive for HBV where approximately 5%-40% individuals are chronically infected. In HIV co-infected individuals, liverrelated mortality is estimated over 17 times higher than those with HBV mono-infection. The spectrum of HIVinduced liver diseases includes hepatitis, steatohepatitis, endothelialitis, necrosis, granulomatosis, cirrhosis and carcinoma. Moreover, HIV co-infection significantly alters the natural history of hepatitis B, and therefore complicates the disease management. Though several studies have demonstrated impact of HIV proteins on hepatocyte biology, only a few data is available on interactions between HBV and HIV proteins. Thus, the clinical spectrum as well as the complexity of the co-infection offers challenging fronts to study the underlying molecular mechanisms, and to design effective therapeutic strategies. Core tip: The consequences of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection on progression of severe liver diseases is a serious public health issue, worldwide. In HIV co-infected individuals, liver-related mortality is estimated over 17 times higher than those with HBV mono-infection. HIV co-infection significantly alters the natural history of hepatitis B, and therefore complicates the disease management. Thus, the clinical spectrum as well as the complexity of the HBV and HIV co-infection of liver offers challenging fronts to study the underlying molecular mechanisms, and to design effective therapeutic strategies.

show abstract

“…29 Thus, lamivudine must be taken into account as an important drug for treatment of people coinfected by HIV/HBV. In our study, which include lamivudine into the antiretroviral three-therapy, 7/14 of the HBV positive women had undetectable viral load, while 5/14 had a high viremy (median : 3128 copies/mL).In a study of Leung et al, 2001, after 3 years of continuous treatment with lamivudine (100 mg daily), 40% (23 of 58) of patients achieved HBeAg seroconversion, and median serum HBV-DNA concentrations were below the level of detection; moreover, the median ALT concentrations were within the normal range throughout 3 years of treatment.…”

mentioning

confidence: 99%

Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa

Ilboudo¹,

Simporé²,

Ouermi³

et al. 2010

Braz J Infect Dis

View full text Add to dashboard Cite

We declare no confl ict of interest. ABSTRACTThe coinfection of HIV and hepatitis B virus (HBV) and their vertical transmission constitute a public health problem in sub-Saharan countries of Africa. The objectives of this research are: i) identify the pregnant women that are coinfected by HIV and HBV at Saint Camille Medical Centre; ii) use three antiretroviral drugs (zidovudine, nevirapine and lamivudine) to interrupt the vertical transmission of HIV and HBV from infected mothers; and iii) use the PCR technique to diagnose children who are vertically infected by these viruses in order to offer them an early medical assistance. At Saint Camille Medical Centre, 115 pregnant women, aged from 19 to 41 years, were diagnosed as HIV-positive and, among them, 14 coinfected with HBV. They had at least 32 weeks of amenorrhoea and all of them received the HAART, which contained lamivudine. Two to six months after childbirth, the babies underwent PCR diagnosis for HIV and HBV. The results revealed that, among these mothers, 64.4% were housewives, 36.5% were illiterates, and only 1.7% had a university degree. The rate of vertical transmission of HIV and HBV was 0.0% (0/115) and 21.4% (3/14), respectively. The 3 mothers who transmitted the HBV to their children had all HBsAg, HbeAg, and HBV DNA positive. An antiretroviral therapy that in addition to zidovudine and nevirapine includes lamivudine could, as in the present study, block or reduce the vertical transmission in HIV positive pregnant women who are coinfected with HBV.

show abstract

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy

Abstract: In this study, entecavir was associated with rapid, clinically significant reductions in HBV DNA, with maintenance of HIV viremia suppression, in HIV/HBV coinfected patients with HBV viremia while on lamivudine treatment.

Cited by 48 publications

References 26 publications

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes

Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes

HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches

Towards the complete eradication of mother-to-child HIV/HBV coinfection at Saint Camille Medical Centre in Burkina Faso, Africa

Contact Info

Product

Resources

About